These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39131711)

  • 1. Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.
    Peyrin-Biroulet L; Colombel JF; Louis E; Ferrante M; Motoya S; Panaccione R; Torres J; Ungaro RC; Kligys K; Kalabic J; Zambrano J; Zhang Y; D'Haens G
    Gastro Hep Adv; 2024; 3(4):539-550. PubMed ID: 39131711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
    Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
    Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
    D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
    Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: a post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies.
    Gao X; Fujii T; Ye BD; Chou JW; Sugimoto K; Cao Q; Kligys K; Murakoshi K; Teng D; Zhang Y; Nakase H
    J Gastroenterol Hepatol; 2024 Jan; 39(1):55-65. PubMed ID: 37788676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    Ferrante M; Irving PM; Abreu MT; Axler J; Gao X; Cao Q; Fujii T; Rausch A; Torres J; Neimark E; Song A; Wallace K; Kligys K; Berg S; Liao X; Zhou Q; Kalabic J; Feagan B; Panaccione R
    J Crohns Colitis; 2024 Mar; 18(3):416-423. PubMed ID: 37797293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
    Schreiber S; Cross RK; Panaccione R; D'Haens G; Bossuyt P; Dotan I; Colombel JF; Louis E; Dubinsky MC; Kligys K; Neimark E; Song A; Zambrano J; Kalabic J; Cheng E; Zhang Y; Ferrante M
    Aliment Pharmacol Ther; 2024 Oct; 60(7):897-906. PubMed ID: 39054592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
    Colombel JF; Schreiber S; D'Haens G; Rizzo J; Kligys K; Griffith J; Zambrano J; Zhou Q; Zhang Y; Kalabic J; Rieder F; Dubinsky MC; Panaccione R
    J Crohns Colitis; 2024 Jun; 18(6):818-827. PubMed ID: 38069472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial.
    Sandborn WJ; Panés J; Danese S; Sharafali Z; Hassanali A; Jacob-Moffatt R; Eden C; Daperno M; Valentine JF; Laharie D; Baía C; Atreya R; Panaccione R; Rydzewska G; Aguilar H; Vermeire S;
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):43-55. PubMed ID: 36240801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
    Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
    Peyrin-Biroulet L; Chapman JC; Colombel JF; Caprioli F; D'Haens G; Ferrante M; Schreiber S; Atreya R; Danese S; Lindsay JO; Bossuyt P; Siegmund B; Irving PM; Panaccione R; Cao Q; Neimark E; Wallace K; Anschutz T; Kligys K; Duan WR; Pivorunas V; Huang X; Berg S; Shu L; Dubinsky M;
    N Engl J Med; 2024 Jul; 391(3):213-223. PubMed ID: 39018531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
    Peyrin-Biroulet L; Ghosh S; Lee SD; Lee WJ; Griffith J; Wallace K; Berg S; Liao X; Panes J; Loftus EV; Louis E
    Aliment Pharmacol Ther; 2023 Mar; 57(5):496-508. PubMed ID: 36266762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
    Fumery M; Defrance A; Roblin X; Altwegg R; Caron B; Hébuterne X; Stefanescu C; Meyer A; Nachury M; Laharie D; Nancey S; Le Berre C; Serrero M; Geyl S; Giletta C; Ah-Soune P; Duveau N; Uzzan M; Abitbol V; Biron A; Tran-Minh ML; Paupard T; Vuitton L; Elgharabawy Y; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2023 Feb; 57(4):426-434. PubMed ID: 36534763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study.
    Ferrante M; Feagan BG; Panés J; Baert F; Louis E; Dewit O; Kaser A; Duan WR; Pang Y; Lee WJ; Gustafson D; Liao X; Wallace K; Kalabic J; D'Haens GR
    J Crohns Colitis; 2021 Dec; 15(12):2001-2010. PubMed ID: 34077509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
    Panaccione R; Ma C; Jairath V; Dignass A; Joshi N; Clark R; Griffith J; Kligys K; Semwal M; Smith Z; Mitchell D; Nunag D; Ferrante M
    J Crohns Colitis; 2024 Aug; ():. PubMed ID: 39212931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.
    Loftus EV; Griffith J; Neimark E; Song A; Wallace K; Nannapaneni S; Zhou J; Byrne R; Kligys K; Pang Y; Liao X; Kalabic J; Dubinsky M
    Adv Ther; 2023 May; 40(5):2311-2325. PubMed ID: 36917429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease.
    Choi D; Sheridan H; Bhat S
    Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.